Exemestane (EXE), an irreversible aromatase inhibitor, is employed as a therapy for hormone-dependent breast cancer. Several studies have also established the budding effects of genistein (GEN) in various types of cancer such as breast, prostate, as well as skin due to its feeble estrogenic and anti-estrogenic properties. Considering the promising benefits of GEN, it was combined with EXE to accomplish superior therapeutic efficiency with fewer side effects. The quantification of the exact concentration of EXE and GEN when delivered as a combination would be required for which HPLC method was developed and validated. For this purpose, the C18 ODS column having dimensions of 150 × 4.6 mm, 5 μm, using mobile phase A as methanol:water (35:15, v/v), with formic acid (0.01%), and B as acetonitrile (in the ratio of A:B−−30:70 v/v) at a flow rate of 1 mL/min was commonly used. The Box− Behnken design was chosen as our experimental model, and the interactions among the independent and dependent variables were analyzed. Parameters like linearity, system suitability, specificity, precision (intra-and interday), robustness, ruggedness, LOD (limit of detection), and LOQ (limit of quantification) were selected for the validation of our proposed method. EXE and GEN were eluted individually at 245 and 270.5 nm, respectively, while both of the agents were determined simultaneously at 256 nm, showing retention time as 2.10 and 1.67 min, respectively, and the calibration plot was observed to be linear in the range of 5−110 μg/mL. Hence, the method that we developed and validated was found to be suitable for the identification of both the drugs simultaneously in combination and in our in-house-developed nanoformulation.

Pharmaceutical industry is moving ahead with the future experiencing an innovation in drug development through the introduction of personalized medicine technologies. Instead of adapting the dose which a patient actually needs, they were adapted to the manufacturer’s dose. Now patient specific or customized method of dosing and dose combinations has superior insistence rather than the standard mass medicines. Printing technology has gained interest during the last years for manufacturing of personalized dosage forms. For manufacturing of personalized drug products three dimensional printing (3DP) has expanded to the pharmaceutical industry. With the approval of first 3DP product an unprecedented opportunity for the discovery of new compounds and technologies has arisen. In this article, we have re-evaluated various printing technology and its utilization in personalized medicines. Further, we also discussed its history, advantages, challenges and various types of printing technologies with advantages and limitations particularly in the area of pharmaceutical research.